Business
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Data from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance, as reflected by the Pro-C3/CTX-III ratio, with associated improvements in Baveno portal hypertension risk categoryPoster presentation on risk reduction in clinically significant portal hypertension designated a TOP Poster at EASL 2026 — selected among the best abstracts in the Portal Hypert
About this update from Galectin Therapeutics Inc.
[{"type":"image","alt":"Galectin Therapeutics Inc.","displaySize":"","headline":null,"caption":"Galectin Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":267,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G6UBow0KDY_0Qy0tpYjQ9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMg--/https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b","width":267,"height":65},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/G6UBow0KDY_0Qy0tpYjQ9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMg--/https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b","width":267,"height":65}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance, as reflected by the Pro-C3/CTX-III ratio, with associated improvements in Baveno portal hypertension risk category","length":323,"tagName":"p"}]},{"val":[{"type":"text","content":"Poster presentation on risk reduction in clinically significant portal hypertension designated a TOP Poster at EASL 2026 — selected among the best abstracts in the Portal Hypertension session and displayed throughout all four days of the congress","length":246,"tagName":"p"}]},{"val":[{"type":"text","content":"Belapectin 2 mg/kg produced a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04), with significantly fewer patients experiencing worsening of liver stiffness as measured by FibroScan®","length":236,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":805,"olType":false},{"type":"text","content":"NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27–30, 2026, in Barcelona, Spain.","length":472,"tagName":"p"},{"type":"text","co...